FDA Approves First Generic Version of Xofluza for Treatment of Influenza

The FDA approved the first generic version of Xofluza (baloxavir marboxil) tablets. This landmark approval, granted to Norwich Pharmaceuticals Inc, introduces a more affordable single-dose option for both the treatment of acute uncomplicated influenza and post-exposure prophylaxis in patients 5 years and older.¹

Arriving just ahead of the 2026–2027 flu season, this development is a milestone in the FDA’s ongoing effort to increase the availability of generic drugs, which currently account for 9 out of every 10 prescriptions filled in the United States.¹

“Today’s approval marks a meaningful milestone for the treatment of influenza,” Iilun Murphy, MD, director of the office of generic drugs in the FDA’s Center for Drug Evaluation and Research, said in a news release.¹ “Expanding patient access to drugs and improving their ease of use are critical public health imperatives, particularly given that influenza alone accounts for millions of illnesses in the US each year.”

For pharmacists, the introduction of generic baloxavir marboxil requires a thorough understanding of its unique pharmacology compared to traditional neuraminidase inhibitors like oseltamivir. Baloxavir marboxil is a first-in-class cap-dependent endonuclease inhibitor that functions as a prodrug, releasing the biologically active baloxavir acid upon administration.^2,3

Unlike older antivirals that prevent the release of new virions, baloxavir interferes with the "cap-snatching" process essential for viral RNA replication, rapidly reducing viral levels in the upper respiratory tract. This distinct mechanism of action is particularly relevant for pharmacy inventory and clinical decision-making, as influenza strains resistant to oseltamivir typically remain susceptible to baloxavir.^2,3

Clinical application and patient counseling remain central to the successful rollout of this generic. The medication is indicated for otherwise healthy patients or those at high risk of complications, provided they have been symptomatic for no more than 48 hours. Pharmacists should note that dosing is weight-based rather than age-dependent for patients over 5 years, including a single 40 mg dose for those weighing between 20 kg and 80 kg and an 80 mg dose for those weighing 80 kg or more. A key counseling point involves the drug's long half-life, which ranges between 80 and 100 hours, necessitating only a single oral dose to complete a full course of treatment.^1-4

Safety and interaction profiles are areas where pharmacists provide essential oversight. Baloxavir marboxil is contraindicated in patients with known hypersensitivity to the drug or its components. Although generally well-tolerated, the most common adverse events include diarrhea, bronchitis, nausea, sinusitis, and headache.^1,3

Pharmacists must specifically alert patients to avoid coadministration with polyvalent cation-containing products, as baloxavir can form chelates with calcium, magnesium, aluminum, iron, and zinc. This means patients should not take the medication with dairy products, calcium-fortified beverages, antacids, or mineral supplements, as these can significantly decrease the drug's bioavailability.^3,4

Furthermore, specialized preparation may be required for younger patients or those with swallowing difficulties. Although the generic approval specifically covers tablets, the brand-name product also exists in granule and suspension forms, and pharmacists are often responsible for preparing the oral liquid. Once mixed, any unused liquid must be discarded after 10 hours, and it should never be mixed with soft foods or other liquids during administration.⁴

Pharmacists should also be aware of the CDC’s current guidance, which does not yet recommend baloxavir for use in pregnant or breastfeeding women, severely immunosuppressed individuals, or hospitalized patients due to a lack of sufficient clinical data for these specific groups.²

As the medical community prepares for the upcoming flu season, the availability of a generic single-dose antiviral offers a potent tool for improving patient compliance and reducing the overall burden of the disease. However, health authorities continue to monitor the development of resistance, specifically the I38T mutation, which can reduce the drug's efficacy. Pharmacists play a vital role in this ecosystem by ensuring appropriate use, managing potential drug-drug interactions, and reminding patients that while antivirals are effective treatments, they are not a substitute for an annual influenza vaccination.^1-4

READ MORE: Influenza Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. FDA approves first single-dose generic treatment for influenza. News release. FDA. June 17, 2026. Accessed June 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-single-dose-generic-treatment-influenza

2. CDC. Influenza antiviral drug baloxavir marboxil. December 19, 2025. Accessed June 18, 2026. https://www.cdc.gov/flu/treatment/baloxavir-marboxil.html

3. Dufrasne F. Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals (Basel). 2021;15(1):28. Published 2021 Dec 24. doi:10.3390/ph15010028

4. Mayo Clinic. Baloxavir marboxil (oral route). June 1, 2026. Accessed June 18, 2026. https://www.mayoclinic.org/drugs-supplements/baloxavir-marboxil-oral-route/description/drg-20452251